




2024

INTERIM REPORT

中智藥業控股有限公司

Zhongzhi Pharmaceutical Holdings Limited

草晶華破壁草本 更好吸收 服用便捷



(Incorporated in the Cayman Islands with limited liability) Stock code: 3737

Content

Corporate Information	2
Business Review and Prospects	4
Management Discussion and Analysis	6
Report on Review of Interim Condensed Consolidated Financial Information	13
Consolidated Statement of Profit or Loss	14
Consolidated Statement of Comprehensive Income	15
Consolidated Statement of Financial Position	16
Consolidated Statement of Changes in Equity	18
Consolidated Statement of Cash Flows	20
Notes to the Interim Condensed Consolidated Financial Information	23
Other Information	44



Corporate Information

BOARD OF DIRECTORS

Executive Directors

Mr. Lai Zhi Tian (Chairman)
Mr. Lai Ying Feng
Mr. Lai Ying Sheng
Mr. Cao Xiao Jun

Non-executive Directors

Ms. Jiang Li Xia
Mr. Peng Zhiyun

Independent Non-executive Directors

Mr. Ng Kwun Wan
Mr. Wong Kam Wah
Mr. Zhou Dai Han

COMMITTEES OF THE BOARD

Audit Committee

Mr. Ng Kwun Wan (Chairman)
Mr. Wong Kam Wah
Mr. Zhou Dai Han

Remuneration Committee

Mr. Wong Kam Wah (Chairman)
Mr. Lai Zhi Tian
Mr. Lai Ying Feng
Mr. Ng Kwun Wan
Mr. Zhou Dai Han

Nomination Committee

Mr. Wong Kam Wah (Chairman)
Mr. Lai Zhi Tian
Mr. Lai Ying Feng
Mr. Ng Kwun Wan
Mr. Zhou Dai Han

AUTHORIZED REPRESENTATIVES

Mr. Lai Ying Feng
Ms. Ho Wing Yan

COMPANY SECRETARY

Ms. Ho Wing Yan

REGISTERED ADDRESS

Windward 3
Regatta Office Park
P.O. Box 1350
Grand Cayman
KY1-1108
Cayman Islands

HEADQUARTER IN THE PRC

No. 3 Kangtai Road South
Torch Development Zone
Zhongshan
Guangdong Province
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Unit 10B, 15/F
Cable TV Tower
9 Hoi Shing Road
Tsuen Wan, New Territories
Hong Kong

OFFICE IN SHENZHEN

Units A-H on the 20th Floor
Dream City Office Tower
Mei Lin Lu, Futian Qu, Shenzhen
PRC

AUDITOR

Ernst & Young

27/F, One Taikoo Place
979 King's Road
Quarry Bay, Hong Kong

Corporate Information

PRINCIPAL BANKER

China Construction Bank Corporation
Bank of Communications Co., Ltd.

CAYMAN ISLANDS PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Ocorian Trust (Cayman) Ltd.
Windward 3
Regatta Office Park
P.O. Box 1350
Grand Cayman
KY1-1108
Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Union Registrars Limited
Suites 3301-04, 33/F.
Two Chinachem Exchange Square
338 King's Road
North Point, Hong Kong

STOCK NAME

ZHONGZHIPHARM

STOCK CODE

3737

COMPANY WEBSITE

www.zeus.cn

草晶华®
破壁草本



Business Review and Prospects

BUSINESS REVIEW AND PROSPECTS

On behalf of the board (the "Board") of directors (the "Directors") of Zhongzhi Pharmaceutical Holdings Limited ("Zhongzhi Pharmaceutical" or the "Company"), together with its subsidiaries (collectively, the "Group"), I am pleased to announce the interim report and the unaudited interim condensed consolidated financial information of the Group for the six months ended 30 June 2024 (the "Reporting Period") to the shareholders of the Company (the "Shareholders").

FUTURE AND OUTLOOK

In 2024, with accelerated development of new quality production forces, the high-quality development of the pharmaceutical industry underwent certain phased adjustments. In the short run, the prices of some traditional Chinese medicinal materials have dramatically increased, putting pressure on the industry. However, the implementation of health prioritization development strategy to satisfy the increasing demand from the public for medical and healthcare services will still drive the healthy development of the pharmaceutical industry.

Pharmaceutical Manufacturing Segment

In 2024, the Company's traditional decoction pieces business has seen steady growth after fine-tuning at early stage and continuous improvement. The main construction of newly established production base of modern Chinese patent medicines of Honeson Pharmaceutical was completed and has started its equipment installation and testing and preparation for compliance inspection. Based on the exploration of new growth points and the strengths in the cell-broken herb field, the Company accelerates the development of new cell-broken herb products and explores new sales channels.

On 3 June, the International Organization for Standardization (ISO) has formally issued the international standards for the ultrafine products of herbs (ISO 6904:2024 Traditional Chinese medicine – General requirements for the ultrafine powder of herbs), which was formulated by the Company, at the ISO/TC249 14th general meeting.

It demonstrates that the innovation in standards for ultrafine products of herbs is recognized and supported by international industry peers. It not only provides a strong guarantee of "standards first" for ultrafine products of herbs entering into the overseas markets but also injects new vitality into promotion and spread of innovative traditional Chinese medicine.

Chain Pharmacies Segment

In 2024, the pharmaceutical retail terminal faced competitive stress from many aspects. The Company has adopted numerous measures to proactively resolve the competitive stress, further optimize the product structure, explore new business, adapt to new consumer habits, and expand the healthcare advantage of Chinese medicine, transiting from therapy services to preventative and healthcare services for the health of the public.

Business Review and Prospects

GRATITUDE

On behalf of the Company, I would like to express my sincere gratitude to all our valued shareholders, customers, suppliers, banks, as well as the management and employees for their continuous trust and support to the Group. We expect the year ahead to be full of challenges, difficulties and opportunities. As always, we will be committed to creating greater value for our shareholders and investors.

By order of the Board

Lai Zhi Tian

Chairman & Executive Director

Hong Kong, 23 August 2024

Management Discussion and Analysis

BUSINESS REVIEW

By virtue of the clear strategic positioning, in 2024, Zhongzhi Pharmaceutical grasped the best strategic pulse of development, successfully formed its unique brand and marketing mode, and conducted organisational transformation, which resulted in high synergy and enabled it to stay at the top of the industry.

- During the Reporting Period, the Group recorded a total revenue of approximately RMB1,088.4 million (corresponding period in 2023: RMB1,094.3 million), representing a decrease of 0.5% over the corresponding period in last year.
- The Group recorded a profit attributable to owners of the parent for the period of approximately RMB83.4 million (corresponding period in 2023: RMB134.9 million), representing a decrease of approximately 38.2% over the corresponding period in last year.
- The basic earnings per share is RMB9.9 cents (corresponding period in 2023: RMB15.9 cents), representing a decrease of approximately 37.7% over the corresponding period in last year.

FINANCIAL ANALYSIS

Revenue

The operation of the Group can be divided into two operating segments, namely (i) pharmaceutical manufacturing and (ii) operation of chain pharmacies. Below is an analysis of revenue by segment.

	Revenue for the six months ended 30 June			% of total revenue for the six months ended 30 June		
	2024 RMB'000	2023 RMB'000	Change (%)	2024 (%)	2023 (%)	Change (%)
Pharmaceutical manufacturing	778,700	772,597	0.8	71.5	70.6	0.9
Operation of chain pharmacies	309,726	321,731	-3.7	28.5	29.4	-0.9
	1,088,426	1,094,328	-0.5	100.0	100.0	

Pharmaceutical Manufacturing

The Group is engaged in the research and development, manufacturing and sale of (i) Chinese patent medicines; and (ii) decoction pieces (consisting of traditional decoction pieces and modern decoction pieces) under the Group's brands in the PRC. The Group's brands include "Zeus (中智)", "Liumian (六棉)" and "Caojinghua (草晶華)".

Revenue derived from pharmaceutical manufacturing increased by approximately 0.8% to RMB778.7 million for the six months ended 30 June 2024 (six months ended 30 June 2023: RMB772.6 million) and accounted for 71.5% of the total revenue during the Reporting Period (six months ended 30 June 2023: 70.6%). The increase in revenue was mainly attributable to the steady growth in traditional decoction pieces and Chinese patent medicines of the Company.

Management Discussion and Analysis

Operation of Chain Pharmacies

The Group has been operating chain pharmacies in Guangdong under the brand “Zeus (中智)” for the sale of pharmaceutical products since 2001. As at 30 June 2024, the Group has 432 self-operated chain pharmacies in Guangdong (as at 30 June 2023: 433), of which 427 are medical insurance designated pharmacies (醫保定點藥店).

Segment revenue of the operation of chain pharmacies decreased by 3.7% to RMB309.7 million for the six months ended 30 June 2024 (six months ended 30 June 2023: RMB321.7 million) and accounted for 28.5% of the total revenue during the Reporting Period (six months ended 30 June 2023: 29.4%), which was mainly attributable to the pharmaceutical retail terminal facing competitive stress from many aspects, leading to a decrease in footfall.

Gross Profit and Gross Profit Margin

Gross profit of the Group for the Reporting Period was RMB627.0 million, representing a decrease of RMB47.9 million or 7.1% as compared with RMB675.0 million for the six months ended 30 June 2023. The analysis of gross profit and gross profit margin by segment is as below:

	Gross profit for the six months ended 30 June			Gross profit margin for the six months ended 30 June		
	2024 RMB'000	2023 RMB'000	Change (%)	2024 (%)	2023 (%)	Change (%)
Pharmaceutical manufacturing	508,810	541,832	-6.1	65.3	70.1	-4.8
Operation of chain pharmacies	118,236	133,131	-11.2	38.2	41.4	-3.2
	627,046	674,963	-7.1	57.6	61.7	-4.1

Pharmaceutical Manufacturing

The gross profit of pharmaceutical manufacturing segment decreased by 6.1% to RMB508.8 million for the six months ended 30 June 2024 (six months ended 30 June 2023: RMB541.8 million). The gross profit margin decreased to 65.3% for the six months ended 30 June 2024 (six months ended 30 June 2023: 70.1%). The decrease in gross profit margin was mainly due to the change in the structure of sales varieties and the increase in the price of some traditional Chinese medicinal materials.

Operation of Chain Pharmacies

The gross profit of chain pharmacies segment decreased by 11.2% to RMB118.2 million for the six months ended 30 June 2024 (six months ended 30 June 2023: RMB133.1 million). The gross profit margin of the chain pharmacies segment decreased to 38.2% for the six months ended 30 June 2024 (six months ended 30 June 2023: 41.4%). The decreased in gross profit margin was mainly due to increased promotional offers provided during the period.

Management Discussion and Analysis

Other Income and Gains

Other income and gains mainly comprise of bank interest income and government grants. For the six months ended 30 June 2024, other income and gains of the Group were approximately RMB18.1 million (six months ended 30 June 2023: RMB25.1 million), representing a decrease of approximately RMB7.0 million as compared to corresponding period in last year, which was mainly attributable to the decrease in the sales of raw materials, investment income and interest income.

Selling and Distribution Expenses

Selling and distribution expenses mainly represent sales-related staff costs, advertisement and promotional costs and rental expenses of the Group's chain pharmacies. Selling and distribution expenses for the six months ended 30 June 2024 amounted to approximately RMB448.5 million (six months ended 30 June 2023: RMB445.0 million), representing an increase of approximately 0.8% as compared to corresponding period in last year. Selling and distribution expenses ratio was 41.2% (six months ended 30 June 2023: 40.7%) against revenue for the six months ended 30 June 2024, representing an increase of 0.5% over the corresponding period in last year, which is mainly due to the increase in the promotion.

Administrative Expenses

Administrative expenses mainly represent expenses and depreciation related to the administrative office and salaries and benefits of the management staff. Administrative expenses amounted to approximately RMB52.6 million for the six months ended 30 June 2024 (six months ended 30 June 2023: RMB53.7 million), representing a decrease of approximately 2.0% as compared to corresponding period in last year. The decrease was mainly due to process optimization.

Income Tax Expense

Income tax expense amounted to approximately RMB20.8 million for the six months ended 30 June 2024 (six months ended 30 June 2023: RMB31.7 million). The decrease was in line with the decrease in profit.

Profit Attributable to Owners of the Parent

As a result of the factors discussed above, profit attributable to owners of the parent decreased by 38.2% to RMB83.4 million for the six months ended 30 June 2024 (six months ended 30 June 2023: RMB134.9 million). The Group's net profit margin was 7.7% for the six months ended 30 June 2024 (six months ended 30 June 2023: 12.3%).

LIQUIDITY AND CAPITAL RESOURCES

Net Current Assets

As at 30 June 2024, the Group had net current assets of approximately RMB276.7 million (31 December 2023: RMB265.5 million). As at 30 June 2024, the Group's total cash and bank balances amounted to approximately RMB162.9 million (31 December 2023: RMB164.4 million). The current ratio of the Group maintained at approximately 1.4 as at 30 June 2024 (31 December 2023: 1.4).

The equity attributable to shareholders of the Company as at 30 June 2024 amounted to approximately RMB1,111.6 million (31 December 2023: RMB1,053.3 million). As at 30 June 2024, the Group had outstanding unsecured borrowings of RMB38.3 million at a floating interest rate and HK\$39.8 million at a floating interest rate (31 December 2023: RMB22.7 million and HK\$30.0 million).

Management Discussion and Analysis

The Group's gearing ratio (borrowings over total equity) as at 30 June 2024 was 6.7% (31 December 2023: 4.8%).

As at 30 June 2024, the Group had available unutilized banking facilities of RMB103.7 million (31 December 2023: RMB119.3 million) and HK\$0.2 million (31 December 2023: HK\$10.0 million).

The Group adopts a centralized management of its financial resources and always maintains a prudent approach for a steady financial position.

Financing

The Board considers that the existing financial resources together with funds generated from business operations will be sufficient to meet future expansion plans and, if necessary, the Group believes that it will be capable of obtaining additional financing with favorable terms.

CAPITAL STRUCTURE

The shares of the Company (the "Shares") were listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on 13 July 2015. The capital of the Company comprises ordinary shares and other reserves. As at 30 June 2024, the number of issued shares of the Company was 863,600,000 ordinary shares of HK\$0.01 each.

FOREIGN EXCHANGE EXPOSURE AND EXCHANGE RATE RISK

The Group's transactions are mainly denominated in RMB. Certain of the Group's cash and bank deposits are denominated in Hong Kong dollars. In addition, the Company will pay dividend in Hong Kong dollars in the future. Any significant exchange rate fluctuations of Hong Kong dollars against RMB may have financial impacts on the Group. The Group did not use any forward contracts, currency borrowings or other means to hedge its foreign currency exposure as at 30 June 2024. Nevertheless, the Group will from time to time review and adjust the Group's hedging and financing strategies based on the RMB and Hong Kong dollars exchange rate movement.

CHARGE ON GROUP ASSETS

As at 30 June 2024 and 31 December 2023, the Group did not have any charges on its assets.

CAPITAL EXPENDITURE

For the six months ended 30 June 2024, the Group had capital expenditure of approximately RMB97.1 million (six months ended 30 June 2023: RMB71.0 million). The capital expenditure was mainly related to the purchase of items of property, plant and equipment and other intangible assets.

INTERIM DIVIDEND

As the Group has commenced the construction of a new factory property and a new product line for expanding its production capacity, and at the same time increased its advertising investment, the Board is proposed not to distribute any interim dividend for the six months ended 30 June 2024 to maintain a healthy cash flow (interim dividend of HK6 cents per ordinary share was distributed for six months ended 30 June 2023).

Management Discussion and Analysis

EMPLOYEES AND EMOLUMENTS POLICY

The key components of the Group's remuneration package included basic salary, and where appropriate, other allowances, commission, bonuses and the Group's contribution to mandatory provident funds or state-managed retirement benefits scheme. Other benefits included share options to be granted under the share option scheme adopted on 8 June 2015, which became effective on the Listing Date, and shares to be granted under the share award plan which was adopted and became effective on 8 January 2016.

As at 30 June 2024, the Group had 2,736 employees with a total remuneration of RMB164.3 million during the Reporting Period (six months ended 30 June 2023: RMB141.4 million) (including pension scheme contributions, staff welfare expenses and equity-settled share award expense). The salaries of the employees are determined with reference to individual performance, work experience, qualification and current industry practices.

The contributions by the Group for the Defined Contribution Schemes are charged to the statement of profit or loss as they become payable in accordance with the relevant rules of the respective schemes.

The Group's contributions to the Defined Contribution Schemes vest fully and immediately with the employees. Accordingly, (i) for each of the two six months ended 30 June 2024 and 30 June 2023, there was no forfeiture of contributions under the Defined Contribution Schemes; and (ii) there were no forfeited contributions available for the Group to reduce its existing level of contributions to the Defined Contribution Schemes as at 30 June 2024 and 30 June 2023. For each of the two six months ended 30 June 2024 and 30 June 2023, the Group did not have any defined benefit plan.

SIGNIFICANT INVESTMENTS

Discloseable Transaction – Construction Contract

On 23 May 2023, Zhongshan Hengsheng Pharmaceutical Group Co., Ltd. (中山市恒生藥業有限公司) ("Zhongshan Hengsheng"), a wholly-owned subsidiary of the Company, entered into the Construction Contract with Shenzhen Xinmei Decoration and Construction Group Limited (深圳新美裝飾建設集團有限公司) ("Shenzhen Xinmei"), pursuant to which Shenzhen Xinmei shall provide construction services to Zhongshan Hengsheng for the construction of the Hengsheng Factory at a consideration of RMB102.0 million.

On 30 June 2024, the above Hengsheng Factory accounted for through construction in progress with a carrying value of approximately RMB85.7 million, which equals to their fair values, accounting for approximately 4.4% of the total assets of the Company. There was no realised or unrealised gains or losses during the Reporting Period.

With the increasing health awareness of the public after the COVID-19 pandemic, Chinese medicine continues to play a fundamental role for medical purpose and healthy lifestyle in the PRC. The demand for the Company's Chinese patent medicines increases steadily as the Group continued to record steady growth on its revenue, and it is expected that the demand in Chinese patent medicines will continue to increase in the future. As such, the Directors are of view that the Group shall expand the production capacity for Chinese patent medicine with the construction of the Hengsheng Factory to further capture market share.

The transaction constitutes a discloseable transaction of the Company and the details are set out in the Company's announcement dated 23 May 2023.

Saved as disclosed herein, the Group had no significant investments held during the Reporting Period.

Management Discussion and Analysis

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

The Group had no material acquisitions or disposals of subsidiaries, associates or joint ventures during the Reporting Period.

EVENT AFTER THE REPORTING PERIOD

There were no significant events after the Reporting Period up to the date of this report.

CAPITAL COMMITMENT

As at 30 June 2024, the Group's capital commitment amounted to RMB19.1 million (31 December 2023: RMB28.5 million). The capital commitment is mainly related to the purchasing of new equipment.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Apart from strengthening the Group's current business and the future plans as disclosed in the Prospectus, the Group will devote its best effort and resources to cope with the increasing market demand in the Group's own-branded products, in order to enhance shareholder's value. The Group will also consider any potential investment opportunities which may benefit its shareholders as and when these opportunities arise.

CONTINGENT LIABILITIES

The Group did not have any contingent liabilities as at 30 June 2024 (31 December 2023: nil).

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities during the Reporting Period and up to the date of this report.

AUDIT COMMITTEE

The Audit Committee was established with written terms of reference which has been adopted for the purpose of reviewing and providing supervision on the financial reporting process and overseeing the risk management and internal control systems of the Group. The Audit Committee comprises three members, all being independent non-executive Directors, namely, Mr. Ng Kwun Wan (Chairman), Mr. Wong Kam Wah and Mr. Zhou Dai Han.

The Audit Committee has reviewed, with the management, the accounting principles and policies adopted by the Group, and discussed the unaudited interim condensed consolidated financial information matters of the Group for the six months ended 30 June 2024 and recommended its adoption by the Board.

Management Discussion and Analysis

CORPORATE GOVERNANCE PRACTICES

The Board of the Company recognises the importance of and is committed to maintaining high standards of corporate governance so as to enhance corporate transparency and safeguard the interests of the Company and its shareholders, customers, staff and other stakeholders. It strives to maintain effective accountability systems through well-developed corporate policies and procedures, and internal systems and controls. The Company has complied with the Code on Corporate Governance Practices (“CG Code”) as set out in the Appendix C1 to the Listing Rules during the six months ended 30 June 2024.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS (THE “MODEL CODE”)

The Company has adopted the Model Code set out in Appendix C3 to the Listing Rules as its code of conduct regarding Directors’ securities transactions. All Directors of the Company have confirmed that, following specific enquiry by the Company, they have complied with the required standards set out in the Model Code throughout the Reporting Period.

Report on Review of Interim Condensed Consolidated Financial Information

To the board of directors of Zhongzhi Pharmaceutical Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

INTRODUCTION

We have reviewed the accompanying interim condensed consolidated financial information set out on pages 14 to 43, which comprises the consolidated statement of financial position of Zhongzhi Pharmaceutical Holdings Limited (the "Company") and its subsidiaries (collectively referred to as the "Group") as at 30 June 2024 and the related consolidated statement of profit or loss, comprehensive income, changes in equity and cash flows for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 Interim Financial Reporting ("IAS 34") issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of this interim condensed consolidated financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim condensed consolidated financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*, issued by the Hong Kong Institute of Certified Public Accountants. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial information is not prepared, in all material respects, in accordance with IAS 34.

Ernst & Young

Certified Public Accountants

Hong Kong

23 August 2024

Consolidated Statement of Profit or Loss

For the six months ended 30 June 2024

	Notes	Six months ended 30 June	
		2024 RMB'000 (Unaudited)	2023 RMB'000 (Unaudited)
REVENUE	4	1,088,426	1,094,328
Cost of sales		(461,380)	(419,365)
Gross profit		627,046	674,963
Other income and gains	4	18,074	25,152
Selling and distribution expenses		(448,475)	(444,956)
Administrative expenses		(52,645)	(53,719)
Other expenses		(34,598)	(29,878)
Finance costs		(4,383)	(3,743)
PROFIT BEFORE TAX	5	105,019	167,819
Income tax expense	6	(20,767)	(31,667)
PROFIT FOR THE PERIOD		84,252	136,152
Attributable to:			
Owners of the parent		83,440	134,900
Non-controlling interests		812	1,252
		84,252	136,152
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
Basic			
— For profit for the period		RMB0.099	RMB0.159
Diluted			
— For profit for the period		RMB0.099	RMB0.159

Consolidated Statement of Comprehensive Income

For the six months ended 30 June 2024

	Six months ended 30 June	
	2024 RMB'000 (Unaudited)	2023 RMB'000 (Unaudited)
PROFIT FOR THE PERIOD	84,252	136,152
OTHER COMPREHENSIVE (LOSS)/INCOME		
Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	(467)	(4,221)
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	252	4,401
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX	(215)	180
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	84,037	136,332
Attributable to:		
Owners of the parent	83,225	135,080
Non-controlling interests	812	1,252
	84,037	136,332

Consolidated Statement of Financial Position

As at 30 June 2024

	Notes	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment	9	578,389	498,367
Investment properties	9	45,728	46,441
Prepayment for property, plant and equipment		2,183	11,878
Right-of-use assets		164,666	165,749
Pledged deposits		100,500	100,000
Goodwill		1,628	1,628
Other intangible assets	10	13,121	14,218
Prepayments		—	850
Equity investments at fair value through profit or loss	11	41,080	42,563
Deferred tax assets		30,464	30,069
Other non-current assets		7,021	6,751
Total non-current assets		984,780	918,514
CURRENT ASSETS			
Inventories	12	344,374	330,017
Trade and notes receivables	13	411,495	327,986
Prepayments, deposits and other receivables	14	58,093	49,473
Equity investments at fair value through profit or loss	11	—	2,277
Cash and cash equivalents	15	162,908	164,368
Total current assets		976,870	874,121
CURRENT LIABILITIES			
Trade and bills payables	16	266,149	190,970
Interest-bearing bank borrowings		36,297	27,329
Other payables and accruals	17	303,092	283,931
Lease liabilities		42,068	48,253
Amounts due to related parties		8,786	8,786
Deferred income	18	9,571	9,756
Tax payable		34,240	39,583
Total current liabilities		700,203	608,608
NET CURRENT ASSETS		276,667	265,513
TOTAL ASSETS LESS CURRENT LIABILITIES		1,261,447	1,184,027

Consolidated Statement of Financial Position

As at 30 June 2024

	Notes	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
NON-CURRENT LIABILITIES			
Deferred income	18	10,212	11,866
Lease liabilities		82,019	76,592
Deferred tax liabilities		19,319	19,553
Interest-bearing bank borrowings		38,271	22,683
Total non-current liabilities		149,821	130,694
Net assets		1,111,626	1,053,333
EQUITY			
Equity attributable to owners of the parent			
Issued capital	19	6,847	6,847
Reserves		1,099,882	1,041,669
		1,106,729	1,048,516
Non-controlling interests		4,897	4,817
Total equity		1,111,626	1,053,333

Consolidated Statement of Changes in Equity

For the six months ended 30 June 2024

	Attributable to owners of the parent												
	Issued capital	Shares held for the share award plan		Share premium	Merger reserve	Statutory surplus reserve	Share-based payment	Share award reserve	Exchange fluctuation reserve	Retained profits	Total	Non-controlling interests	Total equity
		RMB'000	RMB'000										
At 31 December 2023 (audited)	6,847	(25,600)*	86,726*	31,200*	110,743*	5,680*	(2,079)*	18,461*	816,538*	1,048,516	4,817	1,053,333	
Profit for the period	-	-	-	-	-	-	-	-	83,440	83,440	812	84,252	
Other comprehensive income for the period													
Exchange differences on translation of foreign operations	-	-	-	-	-	-	-	(215)	-	(215)	-	(215)	
Total comprehensive (loss)/income for the period	-	-	-	-	-	-	-	(215)	83,440	83,225	812	84,037	
Shares repurchased	-	(1,875)	-	-	-	-	-	-	-	(1,875)	-	(1,875)	
Transfer from retained profits	-	-	-	-	15,158	-	-	-	(15,158)	-	-	-	
Dividend declared	-	-	(23,137)	-	-	-	-	-	-	(23,590)	(732)	(23,869)	
At 30 June 2024 (unaudited)	6,847	(27,475)*	63,589*	31,200*	125,901*	5,680*	(2,079)*	18,246*	884,820*	1,106,729	4,897	1,111,626	

* These reserve accounts comprise the consolidated reserve of RMB1,099,882,000 (31 December 2023: RMB1,041,669,000) in the consolidated statement of financial position.

Consolidated Statement of Changes in Equity

For the six months ended 30 June 2024

	Attributable to owners of the parent											
	Issued capital	Shares held for	Share premium	Merger reserve	Statutory surplus reserve	Share-based payment	Share award reserve	Exchange fluctuation reserve	Retained profits	Total	Non-controlling interests	Total equity
		the share award plan										
At 31 December 2022 (audited)	6,847	(25,600)	202,871	31,200	103,021	5,680	(2,079)	19,551	661,485	1,002,976	2,973	1,005,949
Profit for the period	—	—	—	—	—	—	—	—	134,900	134,900	1,252	136,152
Other comprehensive income for the period												
Exchange differences on translation of foreign operations	—	—	—	—	—	—	—	180	—	180	—	180
Total comprehensive income for the period	—	—	—	—	—	—	—	180	134,900	135,080	1,252	136,332
Capital contribution by a non-controlling shareholder	—	—	—	—	—	—	—	—	—	—	750	750
Transfer from retained profits	—	—	—	—	7,722	—	—	—	(7,722)	—	—	—
Dividend declared	—	—	(69,503)	—	—	—	—	—	—	(69,503)	(264)	(69,767)
At 30 June 2023 (unaudited)	6,847	(25,600)	133,368	31,200	110,743	5,680	(2,079)	19,731	788,663	1,068,553	4,711	1,073,264

Consolidated Statement of Cash Flows

For the six months ended 30 June 2024

	Notes	Six months ended 30 June	
		2024 RMB'000 (Unaudited)	2023 RMB'000 (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		105,019	167,819
Adjustments for:			
Finance costs	5	4,383	3,743
Bank interest income	4	(2,648)	(3,698)
Dividend income from an equity investment at fair value through profit or loss	4	(56)	(32)
Loss/(Gain) on disposal of items of property, plant and equipment	4	136	(849)
Depreciation of property, plant and equipment and investment properties	5	25,039	25,971
Depreciation of right-of-use assets	5	24,453	22,156
Amortisation of other intangible assets	5,10	1,561	1,888
Government grants released	18	(4,473)	(5,260)
Fair value losses/(gains), net:			
Equity investments at fair value through loss or profit	5	—	1,198
Loss/(Gain) on disposal of equity investment at fair value through profit or loss		1,026	(2,053)
Impairment losses on trade receivables	5	3,397	1,490
Write-down of inventories to net realisable value	5	4,961	2,875
		162,798	215,248
(Increase)/Decrease in inventories		(19,318)	17,756
Increase in trade and notes receivables		(106,570)	(17,394)
(Increase)/Decrease in prepayments, deposits and other receivables		(7,770)	1,455
(Increase)/Decrease in non-current assets		(270)	71
Increase/(Decrease) in trade payables		75,179	(22,069)
Increase/(Decrease) in other payables and accruals		30,011	(127,431)
Increase in pledged deposits		(500)	—
Increase in deferred income		2,634	3,881
Cash generated from operations		136,194	71,517
Interest paid		(2,046)	(1,286)
Income tax paid		(26,739)	(30,029)
Net cash flows from operating activities		107,409	40,202

Consolidated Statement of Cash Flows

For the six months ended 30 June 2024

	Notes	Six months ended 30 June	
		2024 RMB'000 (Unaudited)	2023 RMB'000 (Unaudited)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of items of property, plant and equipment		(96,682)	(44,912)
Decrease/(Increase) in prepayments for purchases of property, plant and equipment		9,695	(6,999)
Proceeds from disposal of items of property, plant and equipment		1,012	9,208
Purchase of other intangible assets		(464)	(1,565)
Purchase of land use right		—	(24,567)
Proceeds from disposal of equity investments at fair value through profit or loss		8,573	22,224
Purchase of equity investments at fair value through profit or loss		(5,839)	(37,784)
Purchases of financial assets at fair value through profit or loss		—	(5,000)
Bank interest received	4	2,648	3,698
Dividend received from an equity investment	4	56	32
Net cash flows used in investing activities		(81,001)	(85,665)
CASH FLOWS FROM FINANCING ACTIVITIES			
Principal portion of lease payments		(26,464)	(24,131)
Interest paid		—	(54)
Proceeds from borrowings		42,655	27,229
Repayments of bank borrowings		(18,183)	(29,044)
Dividends paid		(23,137)	(69,503)
Capital contribution by a non-controlling shareholder		—	750
Dividends paid to non-controlling shareholders		—	(264)
Non-controlling interest		(732)	—
Purchase of shares held under the Share Award Plan		(1,875)	—
Net cash flows used in financing activities		(27,736)	(95,017)
NET DECREASE IN CASH AND CASH EQUIVALENTS			
Cash and cash equivalents at beginning of period		124,368	381,010
Exchange of foreign exchange rate changes, net		(132)	1,267
CASH AND CASH EQUIVALENTS AT END OF PERIOD		122,908	241,797

Consolidated Statement of Cash Flows

For the six months ended 30 June 2024

	Notes	Six months ended 30 June	
		2024 RMB'000 (Unaudited)	2023 RMB'000 (Unaudited)
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS			
Cash and bank balances	15	118,908	241,797
Non-pledged time deposits	15	44,000	–
Cash and bank balances as stated in the statement of financial position	15	162,908	241,797
Non-pledged time deposits with original maturity of more than three months when acquired		(40,000)	–
Cash and cash equivalents at end of the period		122,908	241,797

Notes to the Interim Condensed Consolidated Financial Information

1. CORPORATE INFORMATION

Zhongzhi Pharmaceutical Holdings Limited (the "Company") was incorporated in the Cayman Islands on 12 September 2014 as an exempted company with limited liability under the Companies Law (2013 Revision) of the Cayman Islands. The address of the registered office of the Company is Windward 3, Regatta Office Park, P.O. Box 1350, Grand Cayman, KY1-1108, Cayman Islands. The shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on 13 July 2015 (the "Listing Date").

The principal activity of the Company is investment holding. The principal activities of the subsidiaries comprise the manufacture and sale of pharmaceutical products and operation of chain pharmacies in the People's Republic of China (the "PRC"). There has been no significant change in the Group's principal activities during the year.

In the opinion of the Directors, as at the date of this report, the immediate and ultimate holding company of the Company is Crystal Talent Investment Group Limited, a company incorporated in the British Virgin Islands ("BVI").

2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES

2.1 Basis of preparation

The interim condensed consolidated financial information for the six months ended 30 June 2024 has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("Listing Rules"), including compliance with International Accounting Standard ("IAS") 34 *Interim Financial Reporting*.

The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements for the year ended 31 December 2023.

The interim condensed consolidated financial information has been prepared under a historical cost convention, except for equity investments and financial assets at fair value through profit or loss which have been measured at fair value. These financial statements are presented in Renminbi ("RMB") and all values are rounded to the nearest thousand except when otherwise indicated.

2.2 Changes in accounting policies and disclosures

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2023, except for the adoption of the following revised International Financial Reporting Standards ("IFRSs") for the first time for the current period's financial information.

Notes to the Interim Condensed Consolidated Financial Information

2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES

(Continued)

2.2 Changes in accounting policies and disclosures (Continued)

Amendments to IFRS 16	<i>Lease Liability in a Sale and Leaseback</i>
Amendments to IAS 1	<i>Classification of Liabilities as Current or Non-current (the "2020 Amendments")</i>
Amendments to IAS 1	<i>Non-current Liabilities with Covenants (the "2022 Amendments")</i>
Amendments to IAS 7 and IFRS 7	<i>Supplier Finance Arrangements</i>

The nature and impact of the revised IFRSs are described below:

- (a) Amendments to IFRS 16 specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains. Since the Group has no sale and leaseback transactions with variable lease payments that do not depend on an index or a rate occurring from the date of initial application of IFRS 16, the amendments did not have any impact on the financial position or performance of the Group.
- (b) The 2020 Amendments clarify the requirements for classifying liabilities as current or non-current, including what is meant by a right to defer settlement and that a right to defer must exist at the end of the reporting period. Classification of a liability is unaffected by the likelihood that the entity will exercise its right to defer settlement. The amendments also clarify that a liability can be settled in its own equity instruments, and that only if a conversion option in a convertible liability is itself accounted for as an equity instrument would the terms of a liability not impact its classification. The 2022 Amendments further clarify that, among covenants of a liability arising from a loan arrangement, only those with which an entity must comply on or before the reporting date affect the classification of that liability as current or non-current. Additional disclosures are required for non-current liabilities that are subject to the entity complying with future covenants within 12 months after the reporting period.

The Group has reassessed the terms and conditions of its liabilities as at 1 January 2023 and 2024 and concluded that the classification of its liabilities as current or non-current remained unchanged upon initial application of the amendments. Accordingly, the amendments did not have any impact on the financial position or performance of the Group.

- (c) Amendments to IAS 7 and IFRS 7 clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk. The disclosure of relevant information for supplier finance arrangements is not required for any interim reporting period during the first annual reporting period in which an entity applies the amendments. As the Group does not have supplier finance arrangements, the amendments did not have any impact on the interim condensed consolidated financial information.

Notes to the Interim Condensed Consolidated Financial Information

3. OPERATING SEGMENT INFORMATION

The board of directors is the Group's chief operating decision-maker. Management has determined the operating segments based on the information reviewed by the board of directors for the purposes of allocating resources and assessing performance.

For management purposes, the Group is organised into business units based on their products and services and has two reportable operating segments as follows:

- (a) Pharmaceutical manufacturing
- (b) Operation of chain pharmacies

Separate individual financial information for different types of channels is presented to the board of directors who reviews the internal reports in order to assess performance and allocate resources.

Segment results are evaluated based on gross profit. No analysis of the Group's assets and liabilities by operating segments is disclosed as it is not regularly provided to the board of directors.

Intersegment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

Geographical information

Since over 90% of the Group's revenue and operating profit were generated in the PRC and over 90% of the Group's non-current assets were located in the PRC, no geographical segment information in accordance with IFRS 8 *Operating Segments* is presented.

Information about major customers

During each of the six months ended 30 June 2023 and 2024, the Group had no revenue from transaction with a single customer which amounted to 10% or more of the Group's sales.

Notes to the Interim Condensed Consolidated Financial Information

3. OPERATING SEGMENT INFORMATION (Continued)

The revenue and results by operating segments of the Group during each of the six months ended 30 June 2023 and 2024 are as follows:

	Six months ended 30 June 2024		
	Pharmaceutical manufacturing RMB'000 (unaudited)	Operation of chain pharmacies RMB'000 (unaudited)	Total RMB'000 (unaudited)
Segment revenue:			
Revenue from external customers (note 4)	778,700	309,726	1,088,426
Intersegment sales	359,001	—	359,001
	1,137,701	309,726	1,447,427
Reconciliation:			
Elimination of intersegment sales			(359,001)
Revenue			1,088,426
Segment results	508,810	118,236	627,046
Reconciliation:			
Other income and gains			18,074
Selling and distribution expenses			(448,475)
Administrative expenses			(52,645)
Other expenses			(34,598)
Finance costs			(4,383)
Profit before tax			105,019

Notes to the Interim Condensed Consolidated Financial Information

3. OPERATING SEGMENT INFORMATION (Continued)

	Six months ended 30 June 2023		
	Pharmaceutical manufacturing RMB'000 (unaudited)	Operation of chain pharmacies RMB'000 (unaudited)	Total RMB'000 (unaudited)
Segment revenue:			
Revenue from external customers (note 4)	772,597	321,731	1,094,328
Intersegment sales	331,903	—	331,903
	1,104,500	321,731	1,426,231
Reconciliation:			
Elimination of intersegment sales			(331,903)
Revenue			1,094,328
Segment results			
	541,832	133,131	674,963
Reconciliation:			
Other income and gains			25,152
Selling and distribution expenses			(444,956)
Administrative expenses			(53,719)
Other expenses			(29,878)
Finance costs			(3,743)
Profit before tax			
			167,819

Notes to the Interim Condensed Consolidated Financial Information

4. REVENUE, OTHER INCOME AND GAINS

Revenue, which is also the Group's turnover, represents the net invoiced value of goods sold after allowances for returns and trade discounts, for the six months ended 30 June 2024.

For the six months ended 30 June 2024, the revenue from contracts with customers is recognised at a point in time.

An analysis of revenue, other income and gains is as follows:

	Six months ended 30 June	
	2024	2023
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Revenue		
Sale of pharmaceutical products	1,088,426	1,094,328
Other income		
Bank interest income	2,648	3,698
Dividend income	56	32
	2,704	3,730
Gains		
Government grants:		
— Related to assets	1,839	1,322
— Related to income	2,634	3,938
Fair value gain on equity investments and financial assets at fair value through profit or loss	—	2,053
Gain on disposal of items of property, plant and equipment	—	849
Others	10,897	13,260
	15,370	21,422
	18,074	25,152

Notes to the Interim Condensed Consolidated Financial Information

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging:

	Notes	Six months ended 30 June	
		2024 RMB'000 (Unaudited)	2023 RMB'000 (Unaudited)
Cost of inventories sold		461,380	419,365
Depreciation of property, plant and equipment and investment properties		25,039	25,971
Depreciation of right-of-use assets*		24,453	22,156
Amortisation of other intangible assets*	10	1,561	1,888
Research and development costs		22,886	20,551
Advertising, marketing and promotion expenses		307,333	295,960
Write-down of inventories to net realisable value		4,961	2,875
Impairment losses on trade receivables		3,397	1,490
Fair value loss:			
Equity investments at fair value through profit or loss**		—	1,198
Finance costs		4,383	3,743
Auditor's remuneration		1,390	1,268
Employee benefit expenses (including directors' remuneration):			
Wages and salaries		146,096	125,342
Pension scheme contributions (defined contribution scheme)		9,479	8,798
Staff welfare expenses		8,705	7,271
		164,280	141,411

* The depreciation of right-of-use assets and the amortisation of other intangible assets for the reporting period is included in "Administrative expenses", and "Selling and distribution expenses" in the consolidated statement of profit or loss.

** The fair value loss of equity investments at fair value through profit or loss and financial assets at fair value through profit or loss for the reporting period is included in "Other income and gains/Other expenses" in the consolidated statement of profit or loss.

Notes to the Interim Condensed Consolidated Financial Information

6. INCOME TAX EXPENSE

The Group is subject to income tax on an entity basis on profit arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the rules and regulations of the BVI, the Group is not subject to any income tax in the BVI.

Hong Kong profits tax rate is 16.5% (2023:16.5%) of the estimated assessable profit derived from Hong Kong. Since the Group had no such profit during the reporting period, no provision for Hong Kong profits tax has been made.

Taxes on profits assessable in Mainland China have been calculated at the prevailing tax rates, based on existing legislation, interpretations and practices in respect thereof.

Pursuant to the PRC Corporate Income Tax Law effective on 1 January 2008, the PRC corporate income tax rate of the Group's subsidiaries operating in Mainland China during the reporting period was 25% of their taxable profits.

Zhongshan Honeson Pharmaceutical Co.,Ltd. and Zhongshan Zhongzhi Pharmaceutical Group Co., Ltd. are qualified as high and new technology enterprises and are subject to a preferential income tax rate of 15% for the six months ended 30 June 2024 and 2023, respectively.

The income tax expense of the Group for the reporting period are analysed as follows:

	Six months ended 30 June	
	2024	2023
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Mainland China		
Current income tax	21,396	40,983
Deferred income tax benefit	(629)	(9,316)
Total income tax expense	20,767	31,667

In accordance with the Enterprise Income Tax Law of the PRC effective on 1 January 2008, a 10% (or a lower rate if there is a tax treaty between Mainland China and the jurisdiction of the foreign investors) withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in Mainland China. The requirement is effective from 1 January 2008 and applies to earnings after 31 December 2007. The Group is therefore liable to withholding taxes on dividends distributed by the PRC subsidiaries of the Company, in respect of earnings generated from 1 January 2008. As at 30 June 2024, the Group recognised a deferred tax liability of RMB11,643,000 (31 December 2023: RMB10,614,000) in respect of the withholding tax on future dividend distribution by the PRC entities.

Notes to the Interim Condensed Consolidated Financial Information

7. DIVIDEND

During the six months ended 30 June 2023, the Company declared and paid a final dividend (HK6 cents per ordinary share) and a special dividend (HK3 cents per ordinary share) in respect of the previous financial year amounting to HK\$76,230,000 (equivalent to approximately RMB69,503,000), after the adjustment of excluding the dividend for shares held under the share award plan of the Company amounting to HK\$1,494,000 (equivalent to approximately RMB1,362,000).

During the six months ended 30 June 2024, the Company declared and paid a final dividend (HK3 cents per ordinary share) in respect of the previous financial year amounting to HK\$25,410,000 (equivalent to approximately RMB23,137,000), after the adjustment of excluding the dividend for shares held under the share award plan of the Company amounting to HK\$498,000 (equivalent to approximately RMB453,000).

Subsequent to 30 June 2024, the board of directors resolved not to pay any interim dividend to the shareholders (six months ended 30 June 2023: HK\$51,816,000).

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of basic earnings per share for the period is based on the profit for the period attributable to ordinary equity holders of the parent, and the adjusted weighted average number of ordinary shares of 846,837,425 in issue during the period.

The calculation of the diluted earnings per share amount for the period is based on the profit for the period attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation of diluted earnings per share is the adjusted weighted average number of ordinary shares in issue during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise or conversion of all dilutive potential ordinary shares into ordinary shares under the share award plan.

Notes to the Interim Condensed Consolidated Financial Information

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

(Continued)

The calculations of basic and diluted earnings per share are based on:

	Six months ended 30 June	
	2024 RMB'000 (Unaudited)	2023 RMB'000 (Unaudited)
Earnings		
Profit attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	83,440	134,900
	Six months ended 30 June	
	2024 (Unaudited)	2023 (Unaudited)
Shares		
Weighted average number of ordinary shares in issue	863,600,000	863,600,000
Weighted average number of shares held for the share award plan (note 20)	(16,762,575)	(16,601,500)
Adjusted weighted average number of ordinary shares in issue used in the basic earnings per share calculation	846,837,425	846,998,500
Effect of dilution — weighted average number of ordinary shares held for the share award plan	—	—
Adjusted weighted average number of ordinary shares in issue used in the diluted earnings per share calculation	846,837,425	846,998,500

Notes to the Interim Condensed Consolidated Financial Information

9. PROPERTY, PLANT AND EQUIPMENT AND INVESTMENT PROPERTIES

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Carrying amount at 1 January	498,367	421,150
Additions	105,496	145,513
Depreciation provided during the period/year	(24,326)	(48,795)
Transfer to investment properties	—	(2,831)
Disposals	(1,148)	(16,670)
Carrying amount at 30 June/31 December	578,389	498,367

The Group's buildings are located in Mainland China.

As at 31 December 2023 and 30 June 2024, the Group was still in the process of obtaining the property ownership certificates for certain buildings with a net carrying amount of RMB55,171,000 and nil, respectively. The Group is not able to assign, transfer or mortgage the properties until the certificates are obtained.

	Investment properties RMB'000
As at 31 December 2023 and 1 January 2024	46,441
Depreciation provided during the year	(713)
As at 30 June 2024	45,728

Certain self-owned building of the Group was reclassified to investment properties with original cost of RMB57,167,000 and accumulated depreciation of RMB11,439,000. The investment property was stated at cost with fair value not lesser than the carrying amount. The fair value of the investment properties were valued at RMB61,433,000 as at 30 June 2024 by internal appraiser and were determined by income approach.

Notes to the Interim Condensed Consolidated Financial Information

10. OTHER INTANGIBLE ASSETS

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Carrying amount at 1 January	14,218	15,398
Additions	464	2,251
Amortisation provided during the period/year	(1,561)	(3,431)
Carrying amount at 30 June/31 December	13,121	14,218

11. EQUITY INVESTMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Equity investments at fair value through profit or loss		
Listed equity investment, at fair value	—	6,760
Unlisted equity investment, at fair value	41,080	38,080
	41,080	44,840

The above listed equity investment at 30 June 2024 was classified as equity investment at fair value through profit or loss, as equity investments amounting to Nil (31 December 2023: RMB6,760,000) were held for trading purpose, and equity investments amounting to RMB41,080,000 (31 December 2023: RMB38,080,000) were held for strategic investment purpose while the Group has not elected to designate the investments as financial asset at fair value through other comprehensive income.

12. INVENTORIES

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Raw materials	76,600	71,116
Work in progress	27,098	19,602
Finished goods	240,676	239,299
	344,374	330,017

Inventories with a value of RMB23,297,000 (2023: RMB19,995,000) are carried at net realisable value, which is lower than cost.

Notes to the Interim Condensed Consolidated Financial Information

13. TRADE AND NOTES RECEIVABLES

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Trade receivables	301,770	195,894
Less: Impairment of trade receivables	7,258	3,861
Trade receivables, net	294,512	192,033
Notes receivables	116,983	135,953
	411,495	327,986

The Group's trading terms with its wholesale customers are mainly on credit. The credit period is generally not more than three months for major customers. As to new customers and one-off purchase order customers, payment in advance is normally required. Each customer has a maximum credit limit. The Group seeks to enforce strict control over its outstanding receivables. Overdue balances are reviewed regularly by senior management. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers with a good track record, there is no significant concentration of credit risk. Trade receivables are non-interest bearing. The fair value of trade and notes receivables approximates to their carrying amount.

Notes receivables had no historical default and were categorised in stage 1 at 30 June 2024 and 31 December 2023. In calculating the expected credit loss rate, the Group considers the historical loss rate and adjusts for forward-looking macroeconomic data. During the period ended 30 June 2024 and year ended 31 December 2023, the Group estimated that the expected credit loss rate for notes receivables was minimal.

An aged analysis of the trade receivables as at the end of the reporting periods, based on the invoice date, and the balances of notes receivable is as follows:

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Trade receivables:		
Within 1 month	132,960	76,623
1 to 3 months	99,988	71,031
3 to 6 months	47,069	23,815
6 to 12 months	10,429	18,127
Over 12 months	4,066	2,437
	294,512	192,033

The notes receivables are settled within 180 days. As at 30 June 2024, the Group continued to recognise endorsed notes receivable and associated liabilities amounting to RMB10,295,000 (2023: RMB29,959,000) respectively. The directors considered that the Group has retained the substantial risks and rewards, which include default risks relating to such remaining endorsed notes.

Notes to the Interim Condensed Consolidated Financial Information

14. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Prepayments	14,770	15,343
Tax recoverable	7,314	8,471
Deposits and other receivables	36,009	25,659
	58,093	49,473

15. CASH AND CASH EQUIVALENTS

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Cash and bank balances	118,908	121,651
Non-pledged time deposits	144,500	142,717
Less:		
Pledged time deposits*	(100,500)	(100,000)
	162,908	164,368
Denominated in:		
— RMB	155,051	155,524
— HK\$	7,857	8,844
	162,908	164,368

* At 30 June 2024, bank deposits of RMB100,500,000 (31 December 2023: RMB100,000,000) was pledged for bank acceptance bills.

At the end of the reporting period, the cash and bank balances of the Group were denominated in RMB and HK\$. The RMB is not freely convertible into other currencies, however, under Mainland China's Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Notes to the Interim Condensed Consolidated Financial Information

16. TRADE AND BILLS PAYABLES

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Trade payables	148,825	140,766
Bills payables	117,324	50,204
	266,149	190,970

An aged analysis of the trade payables as at 31 December 2023 and 30 June 2024, based on the invoice date, is as follows:

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Within 3 months	130,115	130,594
3 to 6 months	12,365	5,995
6 to 12 months	4,282	2,647
over 12 months	2,063	1,530
	148,825	140,766

The trade payables and bills payables are non-interest-bearing and are normally settled on terms not exceeding 120 days and 180 days, respectively.

17. OTHER PAYABLES AND ACCRUALS

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Accruals and other payables	106,988	98,348
Deposits received	63,548	62,558
Accrued salaries and welfare	32,313	36,387
Endorsed notes	10,295	29,959
Contract liabilities	39,624	23,371
Other tax payables	17,837	9,635
Payables for purchases of property and equipment	32,487	23,673
	303,092	283,931

Other payables are non-interest bearing and have an average term of six months.

Notes to the Interim Condensed Consolidated Financial Information

18. DEFERRED INCOME

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
At 1 January	21,622	32,369
Received amounts	2,634	8,665
Released amounts	(4,473)	(19,412)
At 30 June/31 December	19,783	21,622
Current	9,571	9,756
Non-current	10,212	11,866
	19,783	21,622

19. ISSUED CAPITAL

Issued Capital

The Company's issued share capital during the period is as follows:

	30 June 2024 (Unaudited)	31 December 2023 (Audited)
Issued and fully paid: 863,600,000 (2023: 863,600,000) ordinary shares of HK\$0.01 each (HK\$'000)	8,636	8,636
Equivalent to RMB'000	6,847	6,847

Notes to the Interim Condensed Consolidated Financial Information

20. SHARE AWARD PLAN

A share award plan was adopted on 8 January 2016 (the "Share Award Plan"). The Share Award Plan is a share incentive scheme and is established to recognise the contributions made by certain selected persons and to attract suitable individuals with experience and ability to further develop and expand the business of the Group.

The awarded shares will be either (i) allotted and issued by the Company, by using the general or specific mandates granted or to be granted to the board of directors by the shareholders of the Company at general meetings of the Company from time to time, or (ii) acquired by an independent trustee (the "Trustee") from the open market by utilizing the Company's resources provided to the Trustee. The maximum number of shares in respect of which options may be granted under the Share Award Plan cannot result in the aggregate number of shares awarded by the board of directors throughout the duration of the plan to be in exceeding of 1% of the issued share capital of the Company.

In order to recognise and reward the contribution of and solidify the relationship with the service providers and distributors, the board of directors has resolved to increase the limit of the Share Award Plan from 1% of the issued share capital of the Company to 2.5% of the issued share capital of the Company on 25 March 2019.

Subject to any early termination as may be determined by the board of directors pursuant to the terms of the Share Award Plan, the plan will be valid and effective for a term of 10 years commencing on the date of adoption.

The Company granted 149,000 shares to certain employees on 20 June 2016 and the vesting date of the shares is 20 June 2016. The fair value of the granted shares is calculated based on the closing market price of the shares (HK\$2.37) on the day of the grant, amounting to HK\$353,000 (equivalent to approximately RMB303,000).

The Company granted 1,072,500 shares to certain employees on 7 April 2017 and the vesting date of the shares was 7 April 2017. The fair value of the granted shares is calculated based on the closing market price of the shares (HK\$1.70) on the day of the grant, amounting to HK\$1,823,000 (equivalent to approximately RMB1,618,000).

The Company granted 127,000 shares to certain employees on 2 January 2019 and the vesting date of the shares was 2 January 2019. The fair value of the granted shares is calculated based on the closing market price of the shares (HK\$1.45) on the day of the grant, amounting to HK\$184,000 (equivalent to approximately RMB161,000).

The board of directors also approved to grant certain shares with a maximum number of 5,940,000 shares to certain employees, service providers and distributors (the "Eligible Persons") on 25 March 2019, which was subject to satisfaction of certain performance target for year 2019. As at 31 December 2019, according to the achievement status of performance of the Eligible Persons, 1,200,000 shares were vested while the remaining was forfeited due to failure to meet the performance target. The fair value of the granted shares is calculated based on the closing market price of the shares (HK\$1.439) on the day of the grant, amounting to HK\$1,727,000 (equivalent to approximately RMB1,477,000).

Notes to the Interim Condensed Consolidated Financial Information

20. SHARE AWARD PLAN (Continued)

The Company granted 850,000 shares to certain employees on 2 November 2020 and the vesting date of the shares was 2 November 2020. The fair value of the granted shares is calculated based on the closing market price of the shares (HK\$1.52) on the day of the grant, amounting to HK\$1,292,000 (equivalent to approximately RMB1,117,000).

On 20 October 2020, the board of directors approved to purchase shares as reserve for future granting. From 21 December 2020 to 30 December 2020, the Group purchased 8,677,000 shares in an aggregate amount of HK\$14,268,000 (equivalent to approximately RMB12,322,000).

On 17 June 2021, the board of directors approved to purchase shares as reserve for future grant. On 18 June 2021, the Group purchased 3,323,000 shares in an aggregate amount of HK\$5,288,000 (equivalent to approximately RMB4,383,000).

From 17 June 2024 to 28 June 2024, the Group purchased 1,699,000 shares in an aggregate amount of HK\$2,056,000 (equivalent to approximately RMB1,875,000).

The Group recognised a share award expense of nil for the six months ended 30 June 2024 (2023:Nil).

At the date of approval of this interim condensed consolidated financial information, 18,300,500 shares of the Company are held by the Trustee and have yet to be awarded.

21. COMMITMENTS

Capital commitments

The Group had the following capital commitments at the end of the reporting period:

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Contracted, but not provided for:		
Leasehold improvements	2,716	2,129
Intangible assets	389	272
Plant and machinery	15,992	26,071
	19,097	28,472

At the end of 31 December 2023 and 30 June 2024, the Group had significant authorised but not contracted capital commitment of RMB1,260,000 and RMB199,000, respectively.

Notes to the Interim Condensed Consolidated Financial Information

22. RELATED PARTY TRANSACTIONS

(a) Outstanding balances with related parties

Amounts due to related parties as at 31 December 2023 and 30 June 2024 represent consideration received from the registered shareholders as part of the historical reorganisation. Pursuant to the Contractual Arrangements, the consideration is repayable to the Registered Shareholders upon exercise of the option to repurchase the equity interest of Zhongzhi Herbal Pieces by the Group. The amounts are unsecured, interest-free and have no fixed term of repayment.

(b) Compensation of key management personnel of the Group:

	Six months ended 30 June	
	2024	2023
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Salaries, allowances and benefits in kind	8,321	5,349
Pension scheme contributions	98	96
	8,419	5,445

23. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The carrying amounts and fair values of the Group's financial instruments, other than those with carrying amounts that reasonably approximate to fair values, are as follows:

	Carrying amounts		Fair values	
	30 June	31 December	30 June	31 December
	2024	2023	2024	2023
	RMB'000	RMB'000	RMB'000	RMB'000
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Financial assets				
Pledged deposits, non-current portion	100,500	100,000	100,500	100,000
Equity investments at fair value through profit or loss	41,080	44,840	41,080	44,840
	141,580	144,840	141,580	144,840

Notes to the Interim Condensed Consolidated Financial Information

23. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

The Group's finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer and the audit committee. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of listed equity investments are based on quoted market prices. The fair values of unlisted equity investments designated at fair value through profit or loss have been estimated using a market-based valuation technique based on assumptions that are not supported by observable market prices or rates. The valuation requires the directors to determine comparable public companies (peers) based on industry, size, leverage and strategy, and to calculate an appropriate price multiple, such as enterprise value to earnings before interest and taxes ("EV/EBIT"), for each comparable company identified. The multiple is calculated by dividing the enterprise value of the comparable company by an earnings measure. The trading multiple is then discounted for considerations such as illiquidity and size differences between the comparable companies based on company-specific facts and circumstances. The discounted multiple is applied to the corresponding earnings measure of the unlisted equity investments to measure the fair value. The directors believe that the estimated fair values resulting from the valuation technique, which are recorded in the consolidated statement of financial position, and the related changes in fair values, which are recorded in profit or loss, are reasonable, and that they were the most appropriate values at the end of the reporting period.

The Group invests in unlisted investments, which represent wealth management products issued by banks in Mainland China. The Group has estimated the fair value of these unlisted investments by using a discounted cash flow valuation model based on the market interest rates of instruments with similar terms and risks.

Notes to the Interim Condensed Consolidated Financial Information

23. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2024

	Fair value measurement using			Total RMB'000 (Unaudited)
	Quoted prices in active markets (Level 1) RMB'000 (Unaudited)	Significant observable inputs (Level 2) RMB'000 (Unaudited)	Significant unobservable inputs (Level 3) RMB'000 (Unaudited)	
Equity investment at fair value through profit or loss	—	—	41,080	41,080
Notes receivables	—	116,983	—	116,983
	—	116,983	41,080	158,063

As at 31 December 2023

	Fair value measurement using			Total RMB'000 (Audited)
	Quoted prices in active markets (Level 1) RMB'000 (Audited)	Significant observable inputs (Level 2) RMB'000 (Audited)	Significant unobservable inputs (Level 3) RMB'000 (Audited)	
Equity investment at fair value through profit or loss	6,760	—	38,080	44,840
Notes receivables	—	135,953	—	135,953
Total	6,760	135,953	38,080	180,793

Other Information

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2024, save as disclosed herein, the interests and short positions of the Directors and chief executive in the share capital and underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance ("SFO")), as recorded in the register required to be kept by the Company pursuant to section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transaction By Directors of Listed Issuers (the "Model Code") as set out in Appendix C3 to the Listing Rules, and Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which were taken or deemed to have under such provisions of the SFO) are as follows:

(i) Long position in the ordinary shares of the Company

Name of Director	Beneficial interest Number of ordinary shares	Approximate percentage of the issued share capital of the Company
Mr. Lai Zhi Tian ("Mr. Lai")	14,086,800	1.63%
Mr. Lai Ying Feng	5,990,000	0.69%
Mr. Cao Xiao Jun	3,238,600	0.38%
Mr. Peng Zhiyun	1,231,000	0.14%

Save as disclosed above, none of the Directors or chief executive of the Company and/or any of their respective associates had registered any interests or short positions in any shares and underlying shares in, and debentures of, the Company or any associated corporations as at 30 June 2024, as recorded in the register required to be kept by the Company pursuant to section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to Part XV of the SFO or the Model Code.

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 June 2024, the register of substantial shareholders maintained by the Company pursuant to Section 336 of the SFO shows that other than the interests disclosed in the section headed "Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures" above, the following shareholders had notified the Company of its relevant interests in the issued share capital of the Company.

Other Information

LONG POSITIONS IN THE ORDINARY SHARES OF THE COMPANY

Name	Beneficial interest Number of ordinary shares	Total interest Number of ordinary shares	Approximate percentage of issued share capital of the Company
Crystal Talent (Note 1)	506,922,000	506,922,000	58.70%
Cheer Lik (Note 2)	42,240,000	42,240,000	4.89%
Novich Positioning Investment Limited Partnership (Note 3)	56,958,000	56,958,000	6.60%
Novich Positioning Investment (Cayman) Limited (Note 4)	82,377,000	82,377,000	9.54%

Notes:

1. These 506,922,000 shares are held by Crystal Talent, a company incorporated in the British Virgin Islands with limited liability and is 100% beneficially owned by Mr. Lai.
2. These 42,240,000 shares are held by Cheer Lik, a company incorporated in the British Virgin Islands with limited liability and is 100% beneficially owned by Ms. Jiang Li Xia.
3. These 56,958,000 shares are held by Novich Positioning Investment Limited Partnership, a company incorporated in the Cayman Islands and is 1.09% owned by Novich Positioning Investment (Cayman) Limited.
4. These 82,377,000 shares are held by Novich Positioning Investment (Cayman) Limited, a company incorporated in the Cayman Islands.

Save as disclosed above, the Company has not been notified of any other relevant interests or short positions in the issued share capital of the Company as at 30 June 2024 which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

Other Information

SHARE OPTION SCHEME

A share option scheme was conditionally adopted on 8 June 2015 (the "Share Option Scheme"), which became effective on the Listing Date.

The Share Option Scheme is a share incentive scheme and is established to recognize and motivate the contributions that eligible participants (as defined in the Prospectus) have made or may make to the Group.

The participants of Share Option Scheme includes employees (full time or part-time), executives, Directors (including but not limited to any executive, non-executive and independent non-executive Directors), suppliers, customers, persons providing research, development or other technological support to the Group, shareholder of any entity in which the Group hold at least 20% of its issued share capital, advisor or consultant to any area of business or business development of the Group, any other participants who have contributed or may contribute by way of joint venture, business alliance or other business arrangement of development and growth of the Group are eligible persons under the Share Option Scheme.

Subject to the terms and conditions of the Share Option Scheme, the maximum numbers of shares in respect of which options may be granted under the Share Option Scheme and any other schemes shall not, in aggregate, exceed 10% of the share of the Company in issue at the Listing Date (i.e. 80,000,000 shares) (the "Option Scheme Mandate Limit") unless approved by the shareholders of the Company.

The maximum entitlement for any one participant is that the total number of the Shares issued and to be issued upon exercise of the options granted under the Share Option Scheme to each participant (including both exercised and outstanding options) in any 12-month period shall not exceed 1% of the total number of Shares in issue unless otherwise approved by the Shareholders at a general meeting of the Company.

Any offer to grant of options under the Share Option Scheme to a Director, chief executive or substantial shareholder of the Company or any of their respective associates must be approved by the independent non-executive Directors.

The exercise price for any Share under the Share Option Scheme shall be a price determined by the Board and notified to each grantee and shall not be less than the highest of:

- (i) the closing price of a Share as stated in the Stock Exchange's daily quotations sheet on the date of grant of the relevant option;
- (ii) an amount equivalent to the average closing price of a Share as stated in the Stock Exchange's daily quotations sheets for the five business days immediately preceding the date of grant of the relevant option; and
- (iii) the nominal value of a Share on the offer date.

An option may be exercised in accordance with the terms of the Share Option Scheme at any time during a period as the Board may determine which shall not exceed 10 years from the offer date subject to the provisions of early termination thereof, and provided that the Board may determine the minimum period for which an option has to be held or other restrictions before its exercise.

Save as determined by the Board and provided in the offer of grant of the options, there is no performance target that must be achieved before the options can be exercised. Unless otherwise specified, there is no amount payable on application or acceptance of the options and no specific period within which payments or calls must be made or loans must be repaid.

The vesting period for options shall not be less than 12 months.

Other Information

SHARE OPTION SCHEME (Continued)

An offer for the grant of options shall be deemed to have been accepted when our Company receives the letter containing the offer duly signed by the grantee together with a remittance of HK\$1.00 (or such other nominal sum in any currency as the Board may determine) in favour of our Company as consideration for the grant thereof within such time as may be specified in the offer (which shall not be later than 21 days from the offer date).

Subject to earlier termination by the Company in general meeting or by the Directors, the Share Option Scheme shall be valid and effective for a period of ten years from date of adoption. The remaining life of the Share Option Scheme is 2 years. There is no share option outstanding, granted, exercised, cancelled and lapsed during the period ended 30 June 2024 and since the date of the Shares of the Group listed on the Stock Exchange.

As at the date of this report, the total number of securities available for issue under the Share Option Scheme is 80,000,000, representing approximately 9.26% of the issued shares of the Company.

There were 80,000,000 options available for grant under the Option Scheme Mandate Limit both at the beginning and the end of the period ended 30 June 2024.

The number of shares that may be issued in respect of options granted under the Share Option Scheme during the period ended 30 June 2024 is 0, representing 0% of the weighted average number of shares of the relevant class in issue of the Company for the period ended 30 June 2024.

SHARE AWARD PLAN

A share award plan was adopted on 8 January 2016 (the "Share Award Plan"). The Share Award Plan is a share incentive scheme and is established to recognise the contributions by certain selected persons and to attract suitable individuals with experience and ability to further development and expansion of the Group.

The Board may, in their absolute discretion, determine that any employees (full time or part-time), executives, Directors (including but not limited to any executive, non-executive and independent non-executive Directors), dealers or persons providing services to the Group who have made or can make contributions to the growth and development of the Group will become qualified persons.

The awarded shares will be either (i) allotted and issued by the Company, by using the general or specific mandates granted or to be granted to the board of directors by the shareholders of the Company at general meetings of the Company from time to time, or (ii) acquired by an independent trustee (the "Trustee") from the open market by utilising the Company's resources provided to the Trustee. The maximum number of shares in respect of which options may be granted under the Share Award Plan cannot result in the aggregate number of shares awarded by the board of directors throughout the duration of the plan to be in excess of 1% of the issued share capital of the Company. During the year ended 31 December 2020, 31 December 2021 and 31 December 2022, the Group has acquired 12,000,000 existing shares in total as reserve for future grant. During the six months ended 30 June 2024, the Group did not acquire any shares for future grant.

Any grant of awards (together with options) to a participant in the 12-month period up to and including the date of such grant must not be in aggregate over 1% of the issued shares of the Company.

Other Information

SHARE AWARD PLAN (Continued)

Any grant of awards to a Director (other than an independent non-executive Director) or chief executive of the Company, or any of their associates would result in the shares issued and to be issued in respect of all awards granted (excluding any awards lapsed in accordance with the terms of the Share Award Plan) to such person in the 12-month period up to and including the date of such grant, representing in aggregate over 0.1% of the relevant class of shares in issue, such further grant of awards must be approved by shareholders of the Company in general meeting.

Save as the grant of awarded shares before 31 December 2022, the vesting period for awards shall not be less than 12 months.

Unless otherwise specified, there is no amount payable on application or acceptance of the award and no specific period within which payments or calls must be made or loans must be repaid.

Subject to earlier termination by the Board, the Share Award Plan shall be valid and effective for a period of ten years from the date of adoption. The remaining life of the Share Award Plan is 3 years.

In order to recognise and reward the contribution of and solidify the relationship with the service providers and distributors, the Board has resolved to increase the limit of the Share Award Plan from 1% of the issued share capital of the Company to 2.5% of the issued share capital of the Company on 25 March 2019, i.e. 21,000,000 award shares (the "Award Plan Limit"), representing 2.43% of the current issued share capital of the Company as at the date of this report.

In 2017, the Company granted 1,072,500 shares to certain employees on 7 April 2017 and the vesting date of the shares was 7 April 2017. The fair value of the granted shares is calculated based on the closing market price of the shares (HK\$1.70) on the day of the grant, amounting to HK\$1,823,000 (equivalent to approximately RMB1,618,000).

The Company granted 127,000 shares to certain employees on 2 January 2019 and the vesting date of the shares was 2 January 2019. The fair value of the granted shares is calculated based on the closing market price of the shares (HK\$1.45) on the day of the grant, amounting to HK\$184,000 (equivalent to approximately RMB161,000).

The board of directors also approved to grant certain shares with a maximum number of 5,940,000 shares to certain employees, service providers and distributors (the "Eligible Persons") on 25 March 2019, which was subject to the satisfaction of certain performance target for year 2019. As at 31 December 2019, according to the achievement status of the performance of the Eligible Persons, 1,200,000 shares shall be vested while the remaining was forfeited due to the failure to meet the performance target. The fair value of the granted shares is calculated based on the closing market price of the shares (HK\$1.439) on the day of the grant, amounting to HK\$1,727,000 (equivalent to approximately RMB1,477,000).

The Company granted 850,000 shares to certain employees on 2 November 2020 and the vesting date of the shares was 2 November 2020. The fair value of the granted shares is calculated based on the closing market price of the shares (HK\$1.52) on the day of the grant, amounting to HK\$1,292,000 (equivalent to approximately RMB1,117,000).

Other Information

SHARE AWARD PLAN (Continued)

On 20 October 2020, the board of directors approved to purchase shares as reserve for future grant. From 21 December 2020 to 30 December 2020, the Group purchased 8,677,000 shares in an aggregate amount of HK\$14,268,000 (equivalent to approximately RMB12,322,000).

On 17 June 2021, the board of directors approved to purchase shares as reserve for future grant. On 18 June 2021, the Group purchased 3,323,000 shares in an aggregate amount of HK\$5,288,000 (equivalent to approximately RMB4,383,000).

From 17 June 2024 to 28 June 2024, the Group purchased 1,699,000 shares in an aggregate amount of HK\$2,056,000 (equivalent to approximately RMB1,875,000).

As the date of this report, (i) the Company has not issued and allotted any new shares to the Trustee for the purpose of the Share Award Plan; and (ii) the Company has no intention to issue and allot new shares to the Trustee in the future.

The Group recognised a share award expense of nil for the six months ended 30 June 2023 and 2024 respectively.

As at the date of approval of this interim condensed consolidated financial information, 18,300,500 shares of the Company were held by the Trustee and have yet to be awarded.

There were 18,823,000 awards available for grant under the Award Plan Limit both at the beginning and at the end of the six months ended 30 June 2024.

The number of Shares that may be issued in respect of options and awards granted under all schemes of the Company is 2,177,000, representing 0.25% of the weighted average number of Shares of the relevant class in issue of the Company for the six months ended 30 June 2024.

The particulars of the Share Award Plan during the year ended 31 December 2021 (the "FY2021"), 31 December 2022 (the "FY2022"), 31 December 2023 (the "FY2023") and for the period ended 30 June 2024 are set out below:

	Number of Shares Held for Share Award Plan
At 1 January 2021	13,278,500
Purchased	3,323,000
At 31 December 2021, 31 December 2022, 31 December 2023	16,601,500
Purchased	1,699,000
At 30 June 2024	18,300,500

There is no awarded share outstanding, granted, vested, cancelled and lapsed during FY2021, FY2022, FY2023 and during the period ended 30 June 2024.

Other Information

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Saved as disclosed in the sections "Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures" and "Share Option Scheme" above, at no time during the Reporting Period and up to the date of this report was the Group a party to any arrangements to enable the Directors to acquire by means of acquisition of shares in, or debt securities, and including debentures, of the Group or any other body corporate.

DIRECTORS' INTEREST IN CONTRACTS

Save as disclosed in this report, there was no contract of significance to which the Company or any of its subsidiaries was a party and in which Director(s) had a material interest, whether directly or indirectly, subsisted at the end of the period or at any time during the Reporting Period.

DIRECTORS' INTEREST IN A COMPETING BUSINESS

During the Reporting Period and up to the date of this report, none of the Directors or any of their respective associates has engaged in or has any interest in any business that competes or may compete with the business of the Group, or has any other conflict of interest with the Group.

SUFFICIENCY OF PUBLIC FLOAT

Based on the publicly available information and to the best of the Directors' knowledge, information and belief, the Company had maintained sufficient public float of not less than 25% of its total issued shares as required under the Listing Rules during the Reporting Period and up to the date of this report.

By order of the Board
Mr. Lai Zhi Tian
Chairman & Executive Director

Hong Kong
23 August 2024